Float Short %

16.19

Margin Of Safety %

-24

Put/Call OI Ratio

0.41

EPS Next Q Diff

-0.04

EPS Last/This Y

-0.32

EPS This/Next Y

-0.72

Price

8.47

Target Price

32.45

Analyst Recom

1.33

Performance Q

-23.65

Upside

-481.1%

Beta

0.22

Ticker: KURA

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	KURA	8.64	0.43	0.05	12578
2026-01-26	KURA	8.57	0.43	0.00	12786
2026-01-27	KURA	8.47	0.42	0.00	12889
2026-01-28	KURA	8.03	0.41	0.04	13103
2026-01-29	KURA	8.2	0.41	0.13	13072
2026-01-30	KURA	8.12	0.39	0.01	13522
2026-02-02	KURA	8.27	0.39	0.27	13643
2026-02-03	KURA	8.23	0.38	0.42	13922
2026-02-04	KURA	8.06	0.37	0.85	14206
2026-02-05	KURA	7.4	0.36	0.22	14161
2026-02-06	KURA	7.84	0.36	0.54	14639
2026-02-09	KURA	7.76	0.37	12.65	14875
2026-02-10	KURA	7.84	0.43	0.33	15548
2026-02-11	KURA	7.84	0.42	0.00	15580
2026-02-12	KURA	8.03	0.42	0.00	15614
2026-02-13	KURA	8.32	0.41	0.12	15653
2026-02-17	KURA	8.49	0.41	0.01	15747
2026-02-18	KURA	8.51	0.41	0.04	15803
2026-02-19	KURA	8.57	0.41	1.26	15911
2026-02-20	KURA	8.46	0.41	0.23	16064
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	KURA	8.62	-17.2	-68.0	-2.34
2026-01-26	KURA	8.57	-17.2	-113.0	-2.34
2026-01-27	KURA	8.48	-17.2	-108.4	-2.34
2026-01-28	KURA	8.03	-17.2	-59.8	-2.34
2026-01-29	KURA	8.21	-17.2	-149.8	-2.34
2026-01-30	KURA	8.11	-17.2	-105.3	-2.34
2026-02-02	KURA	8.27	-17.2	-145.4	-2.34
2026-02-03	KURA	8.24	-17.2	-116.1	-2.34
2026-02-04	KURA	8.07	-17.2	-96.5	-2.34
2026-02-05	KURA	7.39	-17.2	-6.3	-2.34
2026-02-06	KURA	7.83	-17.2	-201.7	-2.34
2026-02-09	KURA	7.77	-126.7	-109.5	-2.34
2026-02-10	KURA	7.84	-126.7	-135.3	-2.34
2026-02-11	KURA	7.85	-126.7	-123.0	-2.34
2026-02-12	KURA	8.02	-126.7	-155.8	-2.34
2026-02-13	KURA	8.23	-126.7	-157.3	-2.34
2026-02-17	KURA	8.49	-126.7	-147.1	-2.34
2026-02-18	KURA	8.51	-126.7	-122.1	-2.34
2026-02-19	KURA	8.57	-126.7	-	-2.34
2026-02-20	KURA	8.47	-121.7	-	-2.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	KURA	-1.93	0.51	13.44
2026-01-26	KURA	-1.93	0.50	13.44
2026-01-27	KURA	-1.93	0.50	13.44
2026-01-28	KURA	-3.13	0.50	14.63
2026-01-29	KURA	-3.13	0.50	14.63
2026-01-30	KURA	-3.13	0.50	14.63
2026-02-02	KURA	-3.13	0.16	14.62
2026-02-03	KURA	-3.17	0.16	14.62
2026-02-04	KURA	-3.17	0.16	14.62
2026-02-05	KURA	-3.17	0.16	14.62
2026-02-06	KURA	-3.17	0.16	14.62
2026-02-09	KURA	-3.17	1.05	14.62
2026-02-10	KURA	-3.17	1.05	14.62
2026-02-11	KURA	-3.17	1.05	16.19
2026-02-12	KURA	-3.17	1.05	16.19
2026-02-13	KURA	-3.17	1.05	16.19
2026-02-17	KURA	-4.80	4.78	16.19
2026-02-18	KURA	-4.80	4.78	16.19
2026-02-19	KURA	-4.80	4.78	16.19
2026-02-20	KURA	-4.80	4.78	16.19
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.85

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

-0.89

Insider Transactions

-4.8

Institutional Transactions

4.78

Beta

0.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

6.47

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

75.6

Max Drawdown 5-Year %

-83.6

Target Price

32.45

P/E

Forward P/E

PEG

P/S

7.08

P/B

3.04

P/Free Cash Flow

8.86

EPS

-2.48

Average EPS Est. Cur. Y

-2.34

EPS Next Y. (Est.)

-3.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-208.48

Relative Volume

1.03

Return on Equity vs Sector %

-118.4

Return on Equity vs Industry %

-101

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.03

EBIT Estimation

Kura Oncology, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 192

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.

stock quote shares KURA – Kura Oncology, Inc. Stock Price stock today

news today KURA – Kura Oncology, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KURA – Kura Oncology, Inc. yahoo finance google finance

stock history KURA – Kura Oncology, Inc. invest stock market

stock prices KURA premarket after hours

ticker KURA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: KURA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y